
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc. is positioned for strong revenue growth, particularly from its Signatera molecular residual disease test, which saw a remarkable increase of 21,500 volumes quarter-over-quarter in Q3, reflecting a year-over-year growth of 54%. The company has indicated a potential for expanded reimbursement coverage across additional cancer types, which is expected to enhance average selling prices and improve gross margins. Furthermore, Natera's recent financial performance includes an approximately $80 million revenue beat in Q3 and a significant upward revision of its 2025 revenue guidance by $160 million, underscoring the firm's robust growth trajectory and market confidence.
Bears say
Natera Inc faces potential margin erosion due to reductions in in-network pricing as its total addressable market (TAM) expands, particularly with the inclusion of more average risk patients. The company's growth may be further hindered by regulatory setbacks or delays in product launches, which could negatively impact its ability to expand internationally and achieve market adoption in emerging regions. Furthermore, any shortfall in financial performance or adverse regulatory news presents a significant risk that could adversely affect the company's stock value.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares